RecruitMe Clinical Trial
The Effect of Dispensed Cannabis on Taxane-Induced Peripheral Neuropathy
Cannabinoids for Taxane-Induced Peripheral Neuropathy in Women Undergoing Breast Cancer Treatment
| Sponsor: | Thompson Family Foundation Initiative at Columbia University TFFI |
| Enrolling: | Female Patients Only |
| Study Length: | 8 Weeks |
| Clinic Visits: | 5 |
| Age Range: | Between 21 and 60 years old |
| IRB Number: | 7635 |
| U.S. Government ID: | NCT03782402 |
| Contact: | Diana Martinez, MD: 646-774-7774 / dm437@cumc.columbia.edu |
Additional Study Information:
Paclitaxel is frequently used to treat breast cancer, but it can also cause neuropathy where the nerves of the hands and feet stop working properly. The symptoms of neuropathy can include pain, numbness, and difficulty with everyday activities like walking or typing. Paclitaxel-induced neuropathy is common and there are few treatment options. Our study will test the effect of cannabis (marijuana) capsules on neuropathy caused by paclitaxel (or docetaxel) in breast cancer patients. The capsules are provided by Tilray, a certified medical cannabis producer and the protocol is FDA approved. Our study lasts for 8 weeks, with several visits per month and careful monitoring. Compensation provided for time and travel.
